Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,304 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,827 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06495723 | Polyspecific Antibodies in Lymphoproliferative T-cell Disorders(PALT1) | recruiting | Phase 1 / Phase 2 | 54 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT06678659 | A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer(DAHLIA) | recruiting | Phase 1 / Phase 2 | 170 | Recursion Pharmaceuticals Inc.INDUSTRY | 2 | Aug 20, 2026 |
| clinicaltrials |
| NCT06756308 | A Study of Enasidenib in People With T-Cell Lymphoma | active not recruiting | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07021989 | ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma | recruiting | Phase 2 | 38 | Michael Spinner, MDOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07137481 | Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies | not yet recruiting | Phase 2 | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07275216 | Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | recruiting | Phase 2 | 23 | City of Hope Medical CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT07400029 | A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia | recruiting | Phase 2 | 40 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 20, 2026 | clinicaltrials |
| NCT01810588 | Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation | completed | Phase 2 | 270 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02223208 | Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13) | completed | Phase 1 / Phase 2 | 89 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02966756 | A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | active not recruiting | Phase 2 | 66 | AbbVieINDUSTRY | 4 | Aug 19, 2026 | clinicaltrials |
| NCT03147612 | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia | active not recruiting | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03876769 | Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients(CASSIOPEIA) | active not recruiting | Phase 2 | 121 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 19, 2026 | clinicaltrials |
| NCT04104776 | A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas | recruiting | Phase 1 / Phase 2 | 300 | Novartis PharmaceuticalsINDUSTRY | 7 | Aug 19, 2026 | clinicaltrials |
| NCT05082519 | Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL(IDEAL2) | recruiting | Phase 2 | 240 | Etan OrgelOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05600894 | Venetoclax in Combination With ASTX727 for the Treatment of Chronic Myelomonocytic Leukemia and Other Myelodysplastic Syndrome/Myeloproliferative Neoplasm | active not recruiting | Phase 2 | 132 | National Cancer Institute (NCI)NIH | 2 | Aug 19, 2026 | clinicaltrials |
| NCT05714839 | A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments(DynaMMic-1) | recruiting | Phase 1 / Phase 2 | 123 | GlaxoSmithKlineINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT05977673 | Efficacy and Safety of Frontline Tislelizumab in Patients With de Novo Hodgkin Lymphoma Unsuitable for Standard Frontline Chemotherapy(FIL_Tisle-HL) | recruiting | Phase 2 | 28 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT06106945 | AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma | recruiting | Phase 1 / Phase 2 | 226 | AstraZenecaINDUSTRY | 9 | Aug 19, 2026 | clinicaltrials |
| NCT06137118 | AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia(SYRUS) | recruiting | Phase 1 / Phase 2 | 255 | AstraZenecaINDUSTRY | 13 | Aug 19, 2026 | clinicaltrials |
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07070219 | A Study of CTD402 in T-ALL/LBL Patients(TENACITY-01) | recruiting | Phase 1 / Phase 2 | 118 | Imviva BioINDUSTRY | 2 | Aug 19, 2026 | clinicaltrials |
| NCT07148947 | Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms | recruiting | Phase 2 | 27 | University of WashingtonOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07185373 | Orelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL | recruiting | Phase 2 / Phase 3 | 215 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07228624 | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes | recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07485647 | Identifying Effective and Cost-Conscious Maintenance Daratumumab Dosing | recruiting | Phase 2 | 50 | Eden BiltiboOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07588698 | Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma | not yet recruiting | Phase 2 | 20 | Carrie Ho, MDOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07604233 | Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML | not yet recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07724457 | Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 271 | National Cancer Institute (NCI)NIH | 0 | Aug 19, 2026 | clinicaltrials |
| NCT07763210 | Lazarus: IT Therapy for ICANS | not yet recruiting | Phase 2 | 59 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT07774234 | Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma | not yet recruiting | Phase 2 | 39 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT00923013 | Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT02210078 | Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients With a Persistent Cytomegalovirus Infection | active not recruiting | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03198026 | Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas | active not recruiting | Phase 2 | 29 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03906292 | Frontline Asciminib Combination in Chronic Phase CML(CMLXI) | active not recruiting | Phase 2 | 125 | University of JenaOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04880434 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3)(ZUMA-2) | completed | Phase 2 | 95 | Kite, A Gilead CompanyINDUSTRY | 6 | Aug 18, 2026 | clinicaltrials |
| NCT05701215 | Venetoclax After TKI to Target Persisting Stem Cells in CML(VARIANT) | completed | Phase 2 | 10 | Thomas Ernst, PD Dr. med.OTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06376526 | IMMUNOPLANT for Newly Diagnosed Multiple Myeloma(IMMUNOPLANT) | recruiting | Phase 2 | 150 | Dickran Kazandjian, MDOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06627751 | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease | recruiting | Phase 2 | 28 | Roswell Park Cancer InstituteOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07033598 | Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia(PROSPERA) | recruiting | Phase 2 | 66 | TheradexINDUSTRY | 2 | Aug 18, 2026 | clinicaltrials |
| NCT07153796 | A Phase 1b/2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Combination With Low Intensity Chemotherapy in Older Patients With Newly Diagnosed B-Cell Acute Lymphoblastic Leukemia | active not recruiting | Phase 1 / Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT07770698 | A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia | not yet recruiting | Phase 1 / Phase 2 | 30 | BeOne MedicinesINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT07771361 | BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma and Multiple Myeloma | not yet recruiting | Phase 2 | 90 | Luminary TherapeuticsINDUSTRY | 0 | Aug 18, 2026 | clinicaltrials |
| NCT03943901 | Split-Dose R-CHOP for Older Adults With DLBCL | active not recruiting | Phase 2 | 27 | University of Wisconsin, MadisonOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05850234 | AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)(DURGA-1) | recruiting | Phase 1 / Phase 2 | 232 | AstraZenecaINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05950165 | A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma | active not recruiting | Phase 1 / Phase 2 | 37 | Cho Pharma Inc.INDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06001385 | HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis(OPTIMIZE) | active not recruiting | Phase 2 | 313 | Center for International Blood and Marrow Transplant ResearchNETWORK | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06218602 | Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy. | recruiting | Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07227584 | ALL Backbone in AYAs | recruiting | Phase 2 | 67 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 17, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 20, 2026source: clinicaltrials